Adriano Venditti
University of Rome Tor Vergata
333 Papers
1.6K Citations
Adriano Venditti is an academic researcher from University of Rome Tor Vergata. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 47, co-authored 275 publications. Previous affiliations of Adriano Venditti include Catholic University of the Sacred Heart & Sapienza University of Rome.
Chat about Author
Papers
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
Francesco Lo-Coco,Giuseppe Avvisati,Marco Vignetti,Christian Thiede,Simona Iacobelli,Felicetto Ferrara,Paola Fazi,Laura Cicconi,E. Di Bona,Giorgina Specchia,Simona Sica,Mariadomenica Divona,Alessandro Levis,Walter Fiedler,Elisa Cerqui,Massimo Breccia,Giuseppe Fioritoni,Mario Cazzola,L. Melillo,Enrica Morra,Bernd Hertenstein,Mohammed Wattad,Michael Lübbert,Mathias Hänel,Norbert Schmitz,Alessandro Rambaldi,G. La Nasa,Mario Luppi,Fabio Ciceri,Olimpia Finizio,Adriano Venditti,Francesco Fabbiano,Konstanze Döhner,M. Sauer,Arnold Ganser,Sergio Amadori,Franco Mandelli,Hartmut Döhner,Gerhard Ehninger +38 more
TL;DR: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL.
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Gerrit Jan Schuurhuis,Michael Heuser,Sylvie D. Freeman,Marie C. Béné,Francesco Buccisano,Jacqueline Cloos,David Grimwade,Torsten Haferlach,Robert Kerrin Hills,Christopher S. Hourigan,Jeffrey L. Jorgensen,Wolfgang Kern,Francis Lacombe,Luca Maurillo,Claude Preudhomme,Bert A. van der Reijden,Christian Thiede,Adriano Venditti,Paresh Vyas,Brent L. Wood,Roland B. Walter,Roland B. Walter,Konstanze Döhner,Gail J. Roboz,Gert J. Ossenkoppele +24 more
TL;DR: The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRd in clinical practice.
950
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.
Francesco Passamonti,Chiara Cattaneo,Luca Arcaini,Riccardo Bruna,Michele Cavo,Francesco Merli,Emanuele Angelucci,Mauro Krampera,Roberto Cairoli,Matteo G. Della Porta,Nicola Stefano Fracchiolla,Marco Ladetto,Carlo Gambacorti Passerini,Marco Salvini,Monia Marchetti,Roberto M. Lemoli,Alfredo Molteni,Alessandro Busca,Antonio Cuneo,Alessandra Romano,Nicola Giuliani,Sara Galimberti,Alessandro Corso,Alessandro Morotti,Brunangelo Falini,Atto Billio,Filippo Gherlinzoni,Giuseppe Visani,Maria Chiara Tisi,Agostino Tafuri,Patrizia Tosi,Francesco Lanza,Massimo Massaia,Mauro Turrini,Felicetto Ferrara,Carmela Gurrieri,Daniele Vallisa,Maurizio Martelli,Enrico Derenzini,Attilio Guarini,Annarita Conconi,Annarosa Cuccaro,Laura Cudillo,Domenico Russo,Fabrizio Ciambelli,Anna Maria Scattolin,Mario Luppi,Carmine Selleri,Elettra Ortu La Barbera,Celestino Ferrandina,Nicola Di Renzo,Attilio Olivieri,Monica Bocchia,Massimo Gentile,Francesco Marchesi,Pellegrino Musto,Augusto B. Federici,Anna Candoni,Adriano Venditti,Carmen Fava,Antonio Pinto,Piero Galieni,Luigi Rigacci,Daniele Armiento,Fabrizio Pane,Margherita Oberti,Patrizia Zappasodi,Carlo Visco,Matteo Franchi,Paolo Grossi,Lorenza Bertù,Giovanni Corrao,Livio Pagano,Paolo Corradini +73 more
TL;DR: This study adds to the evidence that patients with haematological malignancies have worse outcomes and the general Italian population with COVID-19 has high mortality, by calculating standardised mortality ratios between observed death in the study cohort and expected death by applying stratum-specific mortality rates.
550
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
Sergio Amadori,Stefan Suciu,Dominik Selleslag,Franco Aversa,Gianluca Gaidano,Maurizio Musso,Luciana Annino,Adriano Venditti,Maria Teresa Voso,Carla Mazzone,Domenico Magro,Paolo de Fabritiis,Petra Muus,Giuliana Alimena,Marco Mancini,Anne Hagemeijer,Francesca Paoloni,Marco Vignetti,Paola Fazi,Liv Meert,Safaa M. Ramadan,Roel Willemze,Theo de Witte,Frédéric Baron +23 more
TL;DR: First-line monotherapy with low-dose GO, as compared with BSC, significantly improved OS in older patients with acute myeloid leukemia who were ineligible for intensive chemotherapy.
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia
Francesco Buccisano,Luca Maurillo,Maria Ilaria Del Principe,Giovanni Del Poeta,Giuseppe Sconocchia,Francesco Lo-Coco,William Arcese,Sergio Amadori,Adriano Venditti +8 more
TL;DR: Evidence supporting the appropriateness of incorporating MRD detection into the AML risk assessment process is examined and a comprehensive prognostic algorithm, generated by combining pretreatment cytogenetics/genetics and posttreatment MRD determination, is recommended.
307